Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies

References

• Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33.
   PubMed Web of Science ®Google Scholar
• Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S195–S203.
   PubMed Web of Science ®Google Scholar
• IHME. Global Burden of Disease Results Tool 2019. Available from: http://ghdx.healthdata.org/gbd-results-tool.
   Google Scholar
• Andersen MA, Vojdeman FJ, Andersen MK, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. Leuk Lymphoma. 2016;57(7):1592–1599.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49(8):1211–1225.
   PubMed Web of Science ®Google Scholar
• Ostrow S, Diggs CH, Sutherland J, et al. Causes of death in patients with non-Hodgkin's lymphoma. Cancer. 1981;48(3):779–782.
   PubMed Web of Science ®Google Scholar
• Oscier D, Dearden C, Eren E, British Committee for Standards in Haematology, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159(5):541–564.
   PubMed Web of Science ®Google Scholar
• Blimark C, Holmberg E, Mellqvist U-H, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–113.
   PubMed Web of Science ®Google Scholar
• Andersen MA, Niemann CU. Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark. Haematologica. 2018;103(7):e330.
   PubMed Web of Science ®Google Scholar
• Teh BW, Tam CS, Handunnetti S, et al. Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. Blood Rev. 2018;32(6):499–507.
   PubMed Web of Science ®Google Scholar
• Andersen MA, Eriksen CT, Brieghel C, et al. Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study. Haematologica. 2018;103(7):e300–e303.
   PubMed Web of Science ®Google Scholar
• Rusu RA, Sîrbu D, Curşeu D, et al. Chemotherapy-related infectious complications in patients with hematologic malignancies. J Res Med Sci. 2018;23:68.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Hulin C, Dimopoulos MA, et al. A predictive model for risk of early grade ≥3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia. 2018;32(6):1404–1413.
   PubMed Web of Science ®Google Scholar
• Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106–111.
   PubMed Web of Science ®Google Scholar
• Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg). In: Agency EM, editor. London, 2018.
   Google Scholar
• Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017;188(3):333–341.
   PubMed Web of Science ®Google Scholar
• Clinical guidelines for immunoglobulin use. In: (UK) DoH, editor. 2nd ed. 2011.
   Google Scholar
• Benbrahim O, Viallard J-F, Choquet S, et al. The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments. Hematology. 2019;24(1):173–182.
   PubMed Web of Science ®Google Scholar
• Barmettler S, Ong M-S, Farmer JR, et al. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169.
   PubMed Web of Science ®Google Scholar
• Reiser M, Borte M, Huscher D, et al. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: long-term data of the SIGNS study. Eur J Haematol. 2017;99(2):169–177.
   PubMed Web of Science ®Google Scholar
• Legendre P, Chahwan D, Marjanovic Z, et al. Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): a retrospective multicenter study. Clin Immunol. 2020;215:108419.
   PubMed Web of Science ®Google Scholar
• Agostini C, Blau IW, Kimby E, et al. Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion. Expert Rev Clin Immunol. 2016;12(9):921–926.
   PubMed Web of Science ®Google Scholar
• Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36.
   PubMed Web of Science ®Google Scholar
• Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96(5):644–647.
   PubMed Web of Science ®Google Scholar
• Trevethan R. Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice. Front Public Health. 2017;5:307.
   Google Scholar
• Ruddy JD, Cormack SJ, Whiteley R, et al. Modeling the risk of team sport injuries: a narrative review of different statistical approaches. Front Physiol. 2019;10:829.
   PubMed Web of Science ®Google Scholar
• Whiteley R. Screening and likelihood ratio infographic. Br J Sports Med. 2016; 50(14):837–838.
   PubMed Web of Science ®Google Scholar
• Kesson A. Predictive Values, Sensitivity and Specificity in Clinical Virology 2009. [18.01.2021]. Available from: http://www.virologyresearch.unsw.edu.au/virology/wp-content/uploads/2013/08/VIM09_AlisonKesson_ClinicalVirology.pdf.
   Google Scholar
• Kelesidis T, Daikos G, Boumpas D, et al. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011;15(1):e2–e16.
   PubMed Web of Science ®Google Scholar
• Park JH, Romero FA, Taur Y, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-Cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis. 2018;67(4):533–540.
   PubMed Web of Science ®Google Scholar
• Hilal T, Gea-Banacloche JC, Leis JF. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Rev. 2018;32(5):387–399.
   PubMed Web of Science ®Google Scholar
• Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(2 Suppl 1):S9–S56.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Ahmedzai SH, Ashcroft J, Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol. 2011;154(1):76–103.
   PubMed Web of Science ®Google Scholar
• Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia. In: (Australia) NBA, editor. 2nd ed. 2012.
   Google Scholar
• Na IK, Buckland M, Agostini C, et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol. 2019;102(6):447–456.
   PubMed Web of Science ®Google Scholar
• Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1–S46.
   PubMed Web of Science ®Google Scholar
• Edgar JDM, Richter AG, Huissoon AP, United Kingdom Primary Immunodeficiency Network (UKPIN) Immunoglobulin Decision to Treat Study Group, et al. Prescribing immunoglobulin replacement therapy for patients with non-classical and secondary antibody deficiency: an analysis of the practice of clinical immunologists in the UK and republic of Ireland. J Clin Immunol. 2018;38(2):204–213.
   PubMed Web of Science ®Google Scholar
• Jolles S, Michallet M, Agostini C, et al. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. Eur J Haematol. 2021;106(4):439–449.
   PubMed Web of Science ®Google Scholar
• Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353(10):988–998.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, Infectious Diseases Society of America, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56–e93.
   PubMed Web of Science ®Google Scholar
• Compagno N, Malipiero G, Cinetto F, et al. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626.
   PubMed Web of Science ®Google Scholar
• Eom TH, Lee HS, Jang PS, et al. Valproate-induced panhypogammaglobulinemia. Neurol Sci. 2013;34(6):1003–1004.
   PubMed Web of Science ®Google Scholar
• Ozdemir H, Sumer S, Karabagli H, et al. B cell aplasia and hypogammaglobulinemia associated with levetiracetam. Ann Saudi Med. 2018;38(1):65–68.
   PubMed Web of Science ®Google Scholar
• Spadaro G, Pecoraro A, De Renzo A, et al. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia. Clin Immunol. 2016;166-167:103–104.
   PubMed Web of Science ®Google Scholar
• Benbrahim O, Viallard JF, Choquet S, et al. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency. Eur J Haematol. 2018;101(1):48–56.
   PubMed Web of Science ®Google Scholar